Search

Your search keyword '"Stief P"' showing total 1,365 results
Start Over Author "Stief P" Publication Year Range Last 50 years
1,365 results on '"Stief P"'

8. Neural foundation of the diathesis-stress model: longitudinal gray matter volume changes in response to stressful life events in major depressive disorder and healthy controls

Author

Thomas-Odenthal, Florian, Ringwald, Kai, Teutenberg, Lea, Stein, Frederike, Alexander, Nina, Bonnekoh, Linda M., Brosch, Katharina, Dohm, Katharina, Flinkenflügel, Kira, Grotegerd, Dominik, Hahn, Tim, Jansen, Andreas, Leehr, Elisabeth J., Meinert, Susanne, Pfarr, Julia-Katharina, Renz, Harald, Schürmeyer, Navid, Stief, Thomas, Straube, Benjamin, Thiel, Katharina, Usemann, Paula, Winter, Alexandra, Krug, Axel, Nenadić, Igor, Dannlowski, Udo, and Kircher, Tilo

Published
2024
Full Text
View/download PDF

9. Perineale Prostatabiopsie

Author

Pfitzinger, Paulo Leonardo, Askari, Darjusch Andreas, Ivanova, Troya, Hoffmann, Marina, Blajan, Iulia, Atzler, Michael, Stadelmeier, Leo Federico, Apfelbeck, Maria, Chaloupka, Michael, Kazmierczak, Philipp, Stief, Christian, and Enzinger, Benazir

Published
2024
Full Text
View/download PDF

10. [68Ga]Ga-FAPI-46 PET/CT for penile cancer – a feasibility study

Author

Eismann, Lennert, Ledderose, Stephan T., Enzinger, Benazir, Berg, Elena, Westhofen, Thilo, Rodler, Severin, Schulz, Gerald B., Toms, Johannes, Holzgreve, Adrien, Gildehaus, Franz J., Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Stief, Christian G., Bartenstein, Peter, Schlenker, Boris, and Unterrainer, Lena M.

Published
2024
Full Text
View/download PDF

11. [68 Ga]Ga-FAPI-46 PET/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: initial experiences from a pilot analysis.

Author

Unterrainer, Lena, Eismann, Lennert, Lindner, Simon, Gildehaus, Franz-Josef, Toms, Johannes, Casuscelli, Jozefina, Holzgreve, Adrien, Kunte, Sophie, Cyran, Clemens, Menold, Paula, Karl, Alexander, Unterrainer, Marcus, Ledderose, Stephan, Stief, Christian, Bartenstein, Peter, Kretschmer, Alexander, and Schulz, Gerald

Subjects
Bladder cancer, Cystectomy, FAP, FAPI, PET/CT imaging, Staging, Urothelial carcinoma, Humans, Positron Emission Tomography Computed Tomography, Male, Urinary Bladder Neoplasms, Female, Aged, Cystectomy, Pilot Projects, Middle Aged, Neoplasm Staging, Lymphatic Metastasis, Aged, 80 and over, Lymph Nodes, Gallium Isotopes, Quinolines
Abstract

INTRODUCTION: [68 Ga]Ga-FAPI-46 PET/CT is a novel hybrid imaging method that previously showed additional diagnostic value in the assessment of distant urothelial carcinoma lesions. We hypothesized that patients with bladder cancer benefit from [68 Ga]Ga-FAPI-46 PET/CT prior to radical cystectomy for locoregional lymph node staging. MATERIALS AND METHODS: Eighteen patients underwent [68 Ga]Ga-FAPI-46 PET/CT for evaluation of lymph node (LN) status in predefined LN regions. Two hundred twenty-nine intraoperatively removed LN served as histopathological reference standard. RESULTS: Urothelial carcinoma (UC) spread was found in ten LN in seven different regions (14.3%). Hereby, [68 Ga]Ga-FAPI-46 PET/CT was positive in four out of seven regions (57.1%) and showed significantly increased FAPI uptake compared to non-pathological regions. In the remaining three out of seven (42.9%) regions, [68 Ga]Ga-FAPI-46 PET/CT was rated negative since no pathological increased FAPI uptake was detected or the proximity of the urinary tract prevented a differentiation from physiological uptake. CT was inconspicuous in these three regions. In total, two FAP-positive LN regions were found without histopathological counterpart. Overall, sensitivity, specificity, positive predictive value, and negative predictive value were 57.1%, 95.2%, 66.7%, and 93.0% for PET imaging. CONCLUSION: In summary, this innovative [68 Ga]Ga-FAPI-46 PET/CT method showed high specificity and negative predictive value in patients with bladder UC with a future potential to optimize therapy planning.

Published
2024

43. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial.

Author

Holzgreve, Adrien, Unterrainer, Marcus, Adams, Thaiza, Oprea-Lager, Daniela, Goffin, Karolien, Lopci, Egesta, Unterrainer, Lena, Kramer, Kristina, Schmidt-Hegemann, Nina-Sophie, Casuscelli, Jozefina, Stief, Christian, Ricke, Jens, Bartenstein, Peter, Kunz, Wolfgang, Mehrens, Dirk, and Calais, Jeremie

Subjects
Cost-effectiveness analysis, PSMA PET/CT, Primary staging, ProPSMA trial, Prostate cancer, Male, Humans, Positron Emission Tomography Computed Tomography, Cost-Benefit Analysis, Gallium Radioisotopes, Australia, Prostatic Neoplasms, Neoplasm Staging
Abstract

PURPOSE: The proPSMA trial at ten Australian centers demonstrated increased sensitivity and specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status in primary high-risk prostate cancer patients. A cost-effectiveness analysis showed benefits of PSMA PET/CT over conventional imaging for the Australian setting. However, comparable data for other countries are lacking. Therefore, we aimed to verify the cost-effectiveness of PSMA PET/CT in several European countries as well as the USA. METHODS: Clinical data on diagnostic accuracy were derived from the proPSMA trial. Costs for PSMA PET/CT and conventional imaging were taken from reimbursements of national health systems and individual billing information of selected centers in Belgium, Germany, Italy, the Netherlands, and the USA. For comparability, scan duration and the decision tree of the analysis were adopted from the Australian cost-effectiveness study. RESULTS: In contrast to the Australian setting, PSMA PET/CT was primarily associated with increased costs in the studied centers in Europe and the USA. Mainly, the scan duration had an impact on the cost-effectiveness. However, costs for an accurate diagnosis using PSMA PET/CT seemed reasonably low compared to the potential consequential costs of an inaccurate diagnosis. CONCLUSION: We assume that the use of PSMA PET/CT is appropriate from a health economic perspective, but this will need to be verified by a prospective evaluation of patients at initial diagnosis.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results